HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Reports Strongest Quarter In 20 Years Driven By 50% E-commerce Sales Jump

Firm's

Executive Summary

Consumers' significant shift to buying more health products online likely is a permanent trend, says RB CEO Laxman Narasimhan. A 37.4% jump in North America on health product stockpiling drove 13.6% growth in global health business sales.

You may also be interested in...



Reckitt's OTC Sales Slide 40% In 'Exceptionally Weak' Cold & Flu Season

Reckitt reports major drop in OTC sales in Q1 as the cold and flu season was almost wiped out by social distancing measures related to COVID-19. CEO Laxman Narasimhan reveals he has seen green shoots in certain markets where restrictions have started to relax, insisting "there is no question flu will come back."

RB Predicts 'Challenging' Rest Of Year For OTC Business

Reckitt Benckiser is expecting its OTC sales to be hit by a weak cold and flu season this year, as the social distancing measures introduced to quash the COVID-19 outbreak also disrupt the circulation of seasonal illnesses. 

Prestige Consumer Adapts Online Messaging For Pandemic-Shifted Shopping Paradigm

Prestige Consumer boosted marketing spending 17% in its latest quarter to $40.2m with strategies including viral videos and adding messages to branded e-commerce pages to attract online shoppers. Consumer purchases of products rose 7% in the January-March period.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel